Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

Lancet Neurology
Raju KapoorDavid H Miller

Abstract

Partial blockade of voltage-gated sodium channels is neuroprotective in experimental models of inflammatory demyelinating disease. In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis. Patients with secondary progressive multiple sclerosis who attended the National Hospital for Neurology and Neurosurgery or the Royal Free Hospital, London, UK, were eligible for inclusion in this double-blind, parallel-group trial. Patients were randomly assigned via a website by minimisation to receive lamotrigine (target dose 400 mg/day) or placebo for 2 years. Treating physicians, evaluating physicians, and patients were masked to treatment allocation. The primary outcome was the rate of change of partial (central) cerebral volume over 24 months. All patients who were randomly assigned were included in the primary analysis. This trial is registered with ClinicalTrials.gov, NCT00257855. 120 patients were randomly assigned to treatment (87 women and 33 men): 61 to lamotrigine and 59 to placebo. 108 patients were analysed for the primary endpoint: 52 in the lamotrigine group and 56 in the placebo group. The mean change in partial...Continue Reading

References

Dec 1, 1996·Brain : a Journal of Neurology·N A LosseffA J Thompson
Nov 5, 1997·NeuroImage·J Ashburner, K Friston
Apr 23, 2009·Multiple Sclerosis : Clinical and Laboratory Research·L V A E BosmaB M J Uitdehaag

❮ Previous
Next ❯

Citations

Jun 11, 2011·Journal of Neurology·David PalingDavid Miller
Dec 25, 2012·Journal of Neurology·Maria A RoccaMassimo Filippi
Aug 21, 2013·CNS Drugs·Amir-Hadi MaghziEmmanuelle Waubant
Dec 12, 2012·Nature Medicine·Reinhard Hohlfeld
Sep 11, 2012·Brain : a Journal of Neurology·Niels EijkelkampJohn N Wood
Feb 1, 2013·Brain : a Journal of Neurology·Tarunya ArunJacqueline Palace
Mar 23, 2013·Brain : a Journal of Neurology·Damineh MorsaliKenneth J Smith
May 31, 2012·Multiple Sclerosis International·Gençer GençZeki Odabasi
Aug 25, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Robert J FoxKim Zuidwijk
Nov 14, 2013·PloS One·Katie LidsterDavid Baker
Aug 28, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sven G MeuthHeinz Wiendl
Oct 10, 2013·Practical Neurology·Claire M Rice
Nov 30, 2013·Brain : a Journal of Neurology·Sarah Al-IzkiDavid Baker
Mar 19, 2014·Nature Reviews. Neurology·Manuel A FrieseLars Fugger
Jan 22, 2014·CNS Drugs·Nicola De StefanoBernd C Kieseier
Sep 6, 2011·Annual Review of Medicine·Daniel OntanedaJeffrey A Cohen
Aug 13, 2015·Multiple Sclerosis and Related Disorders·David Baker, Sandra Amor
Dec 23, 2015·Expert Review of Neurotherapeutics·J William L Brown, Declan T Chard
Feb 18, 2014·Experimental Neurology·Erik Ellwardt, Frauke Zipp
Jan 6, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Afsaneh ShiraniOlaf Stüve
Nov 17, 2012·Lancet Neurology·Jeroen J G GeurtsRichard A Rudick
Jan 8, 2013·European Journal of Medicinal Chemistry·Naveen MulakayalaSrinivas Oruganti
Apr 9, 2015·NMR in Biomedicine·Maria PetraccaMatilde Inglese
May 15, 2012·Drug Discovery Today·Alan M Palmer, Mohammad S Alavijeh
Apr 20, 2011·FEBS Letters·Petra EhlingSven G Meuth
Jul 14, 2010·Lancet Neurology·Franz Fazekas
Mar 5, 2016·Neurologia Medico-chirurgica·Ryosuke Hanaya, Kazunori Arita
Mar 12, 2016·Trends in Neurosciences·David KremerPatrick Küry
Oct 31, 2014·Annals of Clinical and Translational Neurology·Emmanuelle WaubantDaniel Pelletier
Nov 21, 2013·British Journal of Clinical Pharmacology·Alan M Palmer
Jan 10, 2012·Annals of the New York Academy of Sciences·Shiv SaidhaPeter A Calabresi
Mar 25, 2014·Experimental Neurology·Benjamin SchattlingManuel A Friese
Mar 17, 2011·Mitochondrion·Graham R Campbell, Don J Mahad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.